Compare HPS & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HPS | NPCE |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 485.6M |
| IPO Year | 2003 | 2021 |
| Metric | HPS | NPCE |
|---|---|---|
| Price | $14.52 | $13.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.33 |
| AVG Volume (30 Days) | 49.1K | ★ 192.0K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $99,986,000.00 |
| Revenue This Year | N/A | $0.93 |
| Revenue Next Year | N/A | $25.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.13 |
| 52 Week Low | $13.08 | $7.56 |
| 52 Week High | $15.68 | $18.97 |
| Indicator | HPS | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 38.36 | 41.82 |
| Support Level | $14.38 | $12.47 |
| Resistance Level | $14.49 | $16.96 |
| Average True Range (ATR) | 0.14 | 0.80 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 19.09 | 43.99 |
John Hancock Preferred Income Fund III is a closed-end, diversified management investment company. Its investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve the objectives by investing a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. The portfolio composition of the company consists of the U.S. preferred securities, foreign preferred securities, common stocks, corporate bonds, and the short-term investments.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.